AstraZeneca Infrastructure and Expertise
Leveraging AstraZeneca infrastructure and expertise:
The BioVentureHub Impact Stories
Launched in 2015, AstraZeneca's BioVentureHub has emerged as a groundbreaking, non-profit, innovation hub.
Integrated inside AstraZeneca's R&D centre in Gothenburg, the BioVentureHub offers scale-up companies and academic groups unique access to AstraZeneca’s advanced laboratories, technological resources and scientific expertise.
The BioVentureHub plays an important role in strengthening the life science ecosystem and accelerating SME growth. It does this by bringing together diverse scientific talent and approaches, by fostering a ‘dare-to-share’ community culture and by facilitating knowledge sharing, mutual growth and collaborative innovation.
Also, by incorporating SMEs with strategic relevance to AstraZeneca, the BioVentureHub enhances synergistic potential, creating significant value for all involved.
Growing innovation together – turning challenges into opportunities
The BioVentureHub is an important connection between AstraZeneca and the wider life science community, driving advancements in drug discovery and development, medtech, deeptech, diagnostics and digital health solutions.
It effectively tackles the primary challenges facing emerging life science companies, namely accessing necessary resources and specialized expertise.
Through infrastructure sharing, knowledge exchange, and fostering a collaborative dare-to-share culture, the BioVentureHub enables smaller companies to accelerate their R&D processes, navigate complex regulatory landscapes, and achieve crucial milestones.
Alumni success stories
A testament to the success of the BioVentureHub is evident in the growth stories of three of its alumni companies based at GoCo Health Innovation City.
OnDosis, Promimic, and I-Tech leveraged the resources and expertise available at the BioVentureHub to accelerate their development, secure investments and reach significant business milestones.
Their journey from the BioVentureHub to GoCo House exemplifies the transformative impact and influence of the BioVentureHub community on the wider ecosystem, as well as on the growth of emerging companies and innovations in the life science sector.
Martin Olovsson, CEO on OnDosis, one of the three companies in this AstraZeneca BioVentureHub Success stories.
I-Tech, a company specializing in marine coatings, experienced significant growth and development during its time at AstraZeneca's BioVentureHub from 2015 to 2023.
I-Tech leveraged the infrastructure, resources, and collaborative environment of the BioVentureHub to enhance its brand, expand its research capabilities and achieve substantial commercial success. enhancing their research and production capabilities.
Founded as a spinoff from AstraZeneca in 2017, OnDosis aimed to revolutionize oral medication delivery with its unique dosage management technology.
The complexities of developing a product that combined drug formulation, device development and digital health components presented significant challenges.
With innovative nanotechnology from Chalmers University, Promimic joined the BioVentureHub in 2016 to enhance HAnano Surface, their groundbreaking implant surface technology based on synthetic bone minerals.
Upon arrival, Promimic was faced with the challenge of scaling their operations and enhancing their research and production capabilities.
Follow AstraZeneca BioVentureHub on Linkedin: Click here.
Impact Stories about "How the BioVentureHub facilitates collaboration with AstraZeneca": Click here.
Impact Stories about "Cultivating a dare to share culture for life science innovation": Click here.
Impact Stories about "BioVentureHub is shaping A Sustainable Future With SustainTech": Click here.
Subscribe to the BioVentureHub Newsletter: Sign up here.